TY  - JOUR
AU  - Garassino, Marina C
AU  - Mazieres, Julien
AU  - Reck, Martin
AU  - Chouaid, Christos
AU  - Bischoff, Helge
AU  - Reinmuth, Niels
AU  - Cove-Smith, Laura
AU  - Mansy, Talal
AU  - Cortinovis, Diego
AU  - Migliorino, Maria R
AU  - Delmonte, Angelo
AU  - Sánchez, José Garcia
AU  - Chara Velarde, Luis Enrique
AU  - Bernabe, Reyes
AU  - Paz-Ares, Luis
AU  - Perez, Ignacio Diaz
AU  - Trunova, Nataliya
AU  - Foroutanpour, Kayhan
AU  - Faivre-Finn, Corinne
PY  - 2022
DO  - 10.1016/j.jtho.2022.07.1148
UR  - http://hdl.handle.net/10668/22343
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). Many patients are considered...
LA  - en
KW  - Durvalumab
KW  - Immunotherapy
KW  - Locally advanced
KW  - Non–small-cell lung cancer
KW  - Sequential chemoradiotherapy
KW  - Humans
KW  - Lung Neoplasms
KW  - Neoplasm Staging
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Chemoradiotherapy
TI  - Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
TY  - research article
VL  - 17
ER  -